281 related articles for article (PubMed ID: 18257808)
21. Effectiveness of weekly darbepoetin alfa in the treatment of anaemia of HIV-infected haemodialysis patients.
Lucas C; Carrera F; Jorge C; Boquinhas H; Pais MJ
Nephrol Dial Transplant; 2006 Nov; 21(11):3202-6. PubMed ID: 16891651
[TBL] [Abstract][Full Text] [Related]
22. Every-2-week darbepoetin alfa is comparable to rHuEPO in treating chemotherapy-induced anemia. Results of a combined analysis.
Mirtsching B; Charu V; Vadhan-Raj S; Colowick AB; Rossi G; Tomita D; McGuire WP
Oncology (Williston Park); 2002 Oct; 16(10 Suppl 11):31-6. PubMed ID: 12435171
[TBL] [Abstract][Full Text] [Related]
23. Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients.
Nissenson AR; Swan SK; Lindberg JS; Soroka SD; Beatey R; Wang C; Picarello N; McDermott-Vitak A; Maroni BJ
Am J Kidney Dis; 2002 Jul; 40(1):110-8. PubMed ID: 12087568
[TBL] [Abstract][Full Text] [Related]
24. Oxidative stress, inflammation and nutritional status during darbepoetin alpha treatment in peritoneal dialysis patients.
Malgorzewicz S; Lichodziejewska-Niemierko M; Lizakowski S; Liberek T; Lysiak-Szydlowska W; Rutkowski B
Clin Nephrol; 2010 Mar; 73(3):210-5. PubMed ID: 20178720
[TBL] [Abstract][Full Text] [Related]
25. Darbepoetin alfa administered once monthly maintains hemoglobin concentrations in patients with chronic kidney disease.
Ling B; Walczyk M; Agarwal A; Carroll W; Liu W; Brenner R
Clin Nephrol; 2005 May; 63(5):327-34. PubMed ID: 15909591
[TBL] [Abstract][Full Text] [Related]
26. Hemoglobin stability in patients with anemia, CKD, and type 2 diabetes: an analysis of the TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) placebo arm.
Skali H; Lin J; Pfeffer MA; Chen CY; Cooper ME; McMurray JJ; Nissenson AR; Remuzzi G; Rossert J; Parfrey PS; Scott-Douglas NW; Singh AK; Toto R; Uno H; Ivanovich P
Am J Kidney Dis; 2013 Feb; 61(2):238-46. PubMed ID: 23159232
[TBL] [Abstract][Full Text] [Related]
27. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly.
Sulowicz W; Locatelli F; Ryckelynck JP; Balla J; Csiky B; Harris K; Ehrhard P; Beyer U;
Clin J Am Soc Nephrol; 2007 Jul; 2(4):637-46. PubMed ID: 17699476
[TBL] [Abstract][Full Text] [Related]
28. Comparison of darbepoetin alfa and epoetin alfa in the management of anemia of critical illness.
Voils SA; Harpe SH; Brophy GM
Pharmacotherapy; 2007 Apr; 27(4):535-41. PubMed ID: 17381380
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease.
Besarab A; Salifu MO; Lunde NM; Bansal V; Fishbane S; Dougherty FC; Beyer U;
Clin Ther; 2007 Apr; 29(4):626-39. PubMed ID: 17617286
[TBL] [Abstract][Full Text] [Related]
30. Preference for monthly darbepoetin alfa dosing in patients with chronic kidney disease not receiving dialysis.
Hoggard J; Crouch T; McMurray S; Levine M; Prathikanti R; Scarlata D; Audhya P
Curr Med Res Opin; 2006 Oct; 22(10):2023-30. PubMed ID: 17022861
[TBL] [Abstract][Full Text] [Related]
31. Correction of anaemia with darbepoetin alfa in patients with chronic kidney disease receiving dialysis.
Macdougall IC; Matcham J; Gray SJ;
Nephrol Dial Transplant; 2003 Mar; 18(3):576-81. PubMed ID: 12584282
[TBL] [Abstract][Full Text] [Related]
32. Randomized study of darbepoetin alfa and recombinant human erythropoietin for treatment of renal anemia in chronic renal failure patients receiving peritoneal dialysis.
Li WY; Chu TS; Huang JW; Wu MS; Wu KD
J Formos Med Assoc; 2008 Nov; 107(11):843-50. PubMed ID: 18971153
[TBL] [Abstract][Full Text] [Related]
33. Effect of darbepoetin alfa administered once monthly on maintaining hemoglobin levels in older patients with chronic kidney disease.
Silver MR; Agarwal A; Krause M; Lei L; Stehman-Breen C
Am J Geriatr Pharmacother; 2008 Jun; 6(2):49-60. PubMed ID: 18675764
[TBL] [Abstract][Full Text] [Related]
34. Novel erythropoiesis stimulating protein for managing the anemia of chronic kidney disease.
Nissenson AR
Am J Kidney Dis; 2001 Dec; 38(6):1390-7. PubMed ID: 11728981
[TBL] [Abstract][Full Text] [Related]
35. The efficacy of darbepoetin alpha in hemodialysis patients resistant to human recombinant erythropoietin (rHuEpo).
Hejaili F
Saudi J Kidney Dis Transpl; 2009 Jul; 20(4):590-5. PubMed ID: 19587498
[TBL] [Abstract][Full Text] [Related]
36. Dosing strategies for conversion of haemodialysis patients from short-acting erythropoiesis stimulating agents to once-monthly C.E.R.A.: experience from the MIRACEL study.
Dellanna F; Winkler RE; Bozkurt F; Schettler V; Graf S; Bockreiss N; Fliser D;
Int J Clin Pract; 2011 Jan; 65(1):64-72. PubMed ID: 21091595
[TBL] [Abstract][Full Text] [Related]
37. Frequency of administration of erythropoiesis-stimulating agents for the anaemia of end-stage kidney disease in dialysis patients.
Hahn D; Cody JD; Hodson EM
Cochrane Database Syst Rev; 2014 May; 2014(5):CD003895. PubMed ID: 24872328
[TBL] [Abstract][Full Text] [Related]
38. [Resistance index to epoetin alpha and to darbepoetin-alpha in chronic hemodialysis patients: a cohort study].
Pérez-García R; Rodríguez Benítez P; Jofre R; López-Gómez JM; Villaverde MT; Blanco A; Blanco S; Sánchez M
Nefrologia; 2007; 27(3):340-9. PubMed ID: 17725454
[TBL] [Abstract][Full Text] [Related]
39. A comparison of haemoglobin levels and doses in haemodialysis patients treated with subcutaneous or intravenous darbepoetin alfa: a German prospective, randomized, multicentre study.
Bommer J; Asmus G; Wenning M; Bommer G
Nephrol Dial Transplant; 2008 Dec; 23(12):4002-8. PubMed ID: 18676350
[TBL] [Abstract][Full Text] [Related]
40. The continuous erythropoietin receptor activator (C.E.R.A.) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: results of a phase II study.
Provenzano R; Besarab A; Macdougall IC; Ellison DH; Maxwell AP; Sulowicz W; Klinger M; Rutkowski B; Correa-Rotter R; Dougherty FC;
Clin Nephrol; 2007 May; 67(5):306-17. PubMed ID: 17542340
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
